Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.

Oncotarget - 10 Jan 2017

Wen Qing, Dunne Philip D, O'Reilly Paul G, Li Gerald, Bjourson Anthony J, McArt Darragh G, Hamilton Peter W, Zhang Shu-Dong

Abstract excerpt

Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) CRCs, there still remains no effective therapeutic course for advanced KRAS mutant (KRAS-MT) CRC patients.In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin Receptor Antagonists
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Databases, Genetic

Share to Drug Discovery

Share to Gene Regulatory Networks

Share to ras Proteins

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 27965461
DOI: 10.18632/oncotarget.13884
PMCID: PMC5356876

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.PMID 27965461Read ↗

Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapiesSemantic proximity Read ↗

A network-based pharmacological investigation to identify the mechanistic regulatory pathway of andrographolide against colorectal cancerSemantic proximity Read ↗

Network pharmacology-based anti-colorectal cancer activity of piperlonguminine in the ethanolic root extract of Piper longum L.Semantic proximity Read ↗

Targeting Colorectal Cancer Liver Metastasis Through Repurposing Metabolic and Immune Inhibitors : A Theoretical StudySemantic proximity Read ↗

AI-Enhanced RAIN Protocol: A Systematic Approach to Optimize Drug Combinations for Rectal Neoplasm TreatmentSemantic proximity Read ↗

KRAS-Centred Network Analysis Prioritises Indirect Targets and Literature-Supported Drug-Repurposing CandidatesSemantic proximity Read ↗

Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione DerivativesSemantic proximity Read ↗

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in PatientsSemantic proximity Read ↗

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patientsSemantic proximity Read ↗

Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal CancerSemantic proximity Read ↗

Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy.Semantic proximity Read ↗

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.